Drug shortages lead to action

Lee, Jaimy
July 2011
Modern Healthcare;7/18/2011, Vol. 41 Issue 29, p16
Trade Publication
The article reports on the impending drug shortage in the U.S., which prompted the American Hospital Association (AHA) to support legislation that would require the U.S. Food and Drug Administration to notify providers about drug shortages.


Related Articles

  • Record high drug shortages warrant FDA policy changes, AHA tells House health panel.  // AHA News;7/11/2011, Vol. 47 Issue 14, p1 

    The article reports on the action of the U.S. Food and Drug Administration to avoid drug shortages, such as the implementation of the Prescription Drug User Fee Act and the Preserving Access to Life Saving Medications Act.

  • FDA May Alter Rules on Drug Combos.  // Chain Drug Review;9/27/2010, Vol. 32 Issue 16, p93 

    The article reports on the plan of the U.S. Food and Drug Administration (FDA) to change rules enabling manufacturers greater leeway in developing drug combinations.

  • FDA Actions.  // CenterWatch Monthly;Nov2015, Vol. 22 Issue 11, p16 

    A chart is presented depicting a sampling of the U.S. Food and Drug Administration (FDA) regulatory actions taken during October 2015.

  • Laws fail to slow gray market. Lee, Jaimy // Modern Healthcare;10/3/2011, Vol. 41 Issue 40, p14 

    The article expresses the concern of pharmacists and health providers regarding the short supply of drugs sold by secondary distributors. It says that there were 210 cases of drug shortages reported as of September 26, 2011 and that drugs purchased from the gray market were often priced 20 times...

  • Lethal Shortages. Faloon, William // Life Extension;Apr2012, Vol. 18 Issue 4, p1 

    No abstract available.

  • Prices gone wild: Grey market 'scalpers' scoring windfall in American drug market. Woodward, Cal // CMAJ: Canadian Medical Association Journal;2/7/2012, Vol. 184 Issue 2, pE119 

    The article discusses the shortage of vital drugs in the grey market which is being faced by hospitals and health care providers in the U.S. It says that the spread of the grey market has alarmed the U.S. Congress and cast light on outdated drug-supply laws. It mentions that the proposed rules...

  • FDA: Most Drugmakers Meet Postmarketing Commitments. Young, Donna // BioWorld Today;11/11/2010, Vol. 21 Issue 219, p1 

    The article reports on an analysis by Booz-Allen-Hamilton (BAH) of 1,551 backlogged postmarketing studies from 1977 to 2007 which showed that most drug and biologic manufacturers required to complete postmarketing studies are meeting their commitments. According to the results, which were...

  • No Strings Attached. Peters, Rita C. // Drug Discovery & Development;May2012, Vol. 15 Issue 5, p4 

    The author discusses the implications of the reauthorization of the Prescription Drug User Fee Act (PDUFA) in the U.S. She explains that the legislation must be renewed before its expiration date on September 30, 2012 because it may compromise the drug review process and may force the Food and...

  • Dueling draft bills address tracking of pharmaceuticals. Traynor, Kate // American Journal of Health-System Pharmacy;6/15/2013, Vol. 70 Issue 12, p1008 

    The article reports on the draft legislation which was released by U.S. Congress in April 2013, which would create federal standards for monitoring pharmaceuticals that are distributed in the market. A federal track-and-trace electronic system for drug distribution will be implemented, according...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics